Transfer factor in Hodgkin's disease.
In a controlled studiy, six patients with stage-IV Hodgkin's disease were given transfer factor (T.F.) prepared from patients with Hodgkin's disease in long remission. There was an apparent increase in cell-mediated immune responses as evidenced by a significant increase in the recipients' lymphocyte responses to phytohaemagglutinin stimulation. Three out of six patients converted to positive delayed-hypersensitivity tests. These three all had the nodular sclerosing type of Hodgkin's disease. These results warrant the further investigation of the use of Hodgkin's disease-specific T.F. as a therapeutic agent in this condition.
D006689:Hodgkin Disease / Q000276:immunology / Q000628:therapy*; D006801:Humans; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D066298:In Vitro Techniques; D037102:Lectins / Q000494:pharmacology; D007958:Leukocyte Count; D008214:Lymphocytes / Q000276:immunology; D012075:Remission, Spontaneous; D012882:Skin Tests; D013601:T-Lymphocytes / Q000473:pathology; D014165:Transfer Factor / Q000008:administration & dosage / Q000627:therapeutic use*
D037102:Lectins; D014165:Transfer Factor